<DOC>
	<DOCNO>NCT01465997</DOCNO>
	<brief_summary>Compare safety Lacosamide ( LCM ) Carbamazepine Controlled-Release ( CBZ-CR ) monotherapy newly recently newly diagnose subject primary safety variable include spontaneous report Adverse Events ( AEs ) , withdrawal subject due AEs , report Serious AEs ( SAEs ) .</brief_summary>
	<brief_title>Evaluating Long Term Safety Lacosamide ( LCM ) Carbamazepine Controlled-release ( CBZ-CR ) ; Initial Monotherapy Epilepsy Subjects 16 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Subject/legal representative consider reliable capable adhere protocol Subject remain seizure free complete Maintenance Phase SP0993 ; subject experience 1 seizure first second target dose SP0993 Maintenance Phase Subject expect benefit participation SP0994 opinion investigator Subject receive investigational drug use experimental device addition LCM CBZCR Subject experience seizure third target dose Evaluation Phase Maintenance Phase SP0993 study Subject take benzodiazepine nonepilepsy indication Subject meet withdrawal criterion previous study SP0993 Subject experience ongoing SAE previous study SP0993 Subject lifetime history suicide attempt ( include active attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( Yes ) either Question 4 Question 5 Columbia Suicide Severity Rating Scale ( CSSRS ) Screening . Or subject positive response ( Yes ) either Question 4 Question 5 CSSRS Screening `` Since Last Visit '' version</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lacosamide</keyword>
</DOC>